Novo Nordisk Launches Higher Dose Of Wegovy Injection Across US — Retail Thinks Stock Is ‘Terribly Undervalued’

• Novo got approval for the higher dose of its Wegovy injection in March based on results from a late-stage clinical trial in which 89% of participants taking the higher dose achieved 5% or greater weight loss at 72 weeks.
• Novo said on Tuesday that self paying adults prescribed Wegovy HD can expect a price of $399/month.
• In January, Novo also launched its weightloss pill, in a bid to regain market share being eroded by rival Eli Lilly and Co.

Shares of Novo Nordisk (NVO) saw increased retail chatter on Tuesday after the company announced the availability of its higher dose Wegovy injection across the U.S.

On Stocktwits, retail sentiment around NVO stock stayed within the ‘neutral’ territory over the past 24 hours. Retail chatter around the stock jumped 136% over the same time frame.

A Stocktwits user said that NVO stock remains “stubbornly undervalued.”

Another sounded hopes for a big move.

The Wegovy HD injection 7.2 mg will be available through over 70,000 U.S. pharmacies, including Novo’s own NovoCare Pharmacy and select telehealth providers, the company said. The higher dose delivers the highest weight loss of any Wegovy injection to date.  

Wegovy HD Approval

Novo got approval for the higher dose of its Wegovy injection in March based on results from a late-stage clinical trial in which 89% of participants taking the higher dose achieved 5% or greater weight loss at 72 weeks as compared to 38% amongst those taking placebo.

Prior to its approval, the highest approved dose of Wegovy injectable for weight loss was 2.4 mg.

Novo said on Tuesday that self paying adults prescribed Wegovy HD can expect a price of $399/month.

“Whether patients haven't yet reached their weight loss goals on lower-dose Wegovy injectables, or they simply have a more significant amount of weight to lose, the 21% weight loss demonstrated in the STEP UP trial, if all patients stayed on treatment, shows what's possible with this new dose, and that's an opportunity we're excited to provide," said Ed Cinca, senior vice president, Marketing and Patient Solutions at Novo Nordisk.

Novo Outlook

In January, Novo also launched its weightloss pill, in a bid to regain market share being eroded by rival Eli Lilly and Co (LLY).

However, the company now expects its adjusted sales growth for 2026 to be down 5% to 13% at constant exchange rates, owing to lower realised prices and competition, among other factors.

NVO stock is down 42% over the past 12 months. 

Read More: Hyperscale Data Reports $102 Million In Assets, Nearly Double Its Market Cap

For updates and corrections, email newsroom[at]stocktwits[dot]com.